An observational study in Aortic Stenosis, Ascending Aortic Dilatation and Bicuspid Aortic Valve, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by China National Center for Cardiovascular Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Aortic Valve Stenosis with a site in China — 41 open to participants now, 49 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 67 studies in Aortic Valve Stenosis with a site in China, this one is the 10th largest by planned enrollment of the 20 observational ones that give a count, is one of 6 that started in 2022, is one of 20 observational ones, reaches primary completion later than 15 of the 48 other live ones, and was the 31st registered.
1,025 studies on the registry are indexed under Aortic Valve Stenosis; 293 are open to participants now.
Browse Aortic Valve Stenosis studies →41 of the 67 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Yan'an Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18+
Beijing Balance Medical Technology Co., Ltd · Sites in China
Ages 60–100
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 480 is above the median of 200 across 435 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 120 across the 47 interventional studies, 465 across the 20 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 67 have an industry lead sponsor. The 10 most frequent:
China National Center for Cardiovascular Diseases is the lead sponsor of 270 studies on the registry; 142 are open to participants now.
China National Center for Cardiovascular Diseases has 6 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to assess the changes of ascending aortic diameter in patients undergoing transcatheter aortic valve replacement. The main questions it aims to answer are:
Ascending aortic (AA) dilatation occurs frequently in patients with aortic stenosis (AS). For patients who are candidates for transcatheter aortic valve replacement (TAVR), simultaneous repair of a dilatated AA is technically difficult. As the indications for TAVR have extended to low-risk patients and patients with bicuspid aortic valve , AA dilatation should be considered as a new criterion to refine risk stratification in patients undergoing TAVR. In this observational study, we aim to evaluate the changes of AA diameters and identify the determinants post-TAVR AA dilatation.
The indication to perform transcatheter aortic valve replacement was based on a consensus by the Institutional Heart Team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing transfemoral transcatheter aortic valve replacement for aortic stenosis
Procedure: Transcatheter aortic valve replacement
All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
Rate of ascending aortic dilatation
The change of AA diameters (before the procedure and at the latest follow-up) divided by the follow-up period.
Time frame: 1-year and 2-year
Rate of all-cause mortality
All-cause mortality during the follow-up period
Time frame: 1-year and 2-year
Rate of adverse aortic events
Aortic dissection, aortic rupture, and sudden death not attributable to other causes.
Time frame: 1-year and 2-year
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Mar 2025, 35 months after the start.
Of 205 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 35 months is below that.
Counting every sponsor, half of 242 studies reached it within 42 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →